CompletedNot Applicable

Metabonomic of Patients With Hepatitis B Cirrhosis Complicated With Sarcopenia.

China60 participantsStarted 2021-08-17

Plain-language summary

Sarcopenia is a common complication in liver cirrhosis patients and has been confirmed that associated with poor prognosis. China has the world's largest burden of hepatitis B virus-related liver cirrhosis (HBV-related liver cirrhosis). However, the relationship between HBV-related liver cirrhosis patients with muscle mass loss and normal muscle mass is remain largely unknown. Our study aimed to reveal the metabolic profile and identify potential biomarkers of muscle mass loss in HBV-related liver cirrhosis.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. the diagnostic criteria for decompensation of liver cirrhosis of chronic viral hepatitis B formulated according to the Guidelines for Diagnosis and Treatment of Liver Cirrhosis issued by the Chinese Society of Hepatology in 2019
✓. The diagnosis of muscle mass loss conforms to SMI less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
✓. Patients aged between 18 and 60 years old
✓. Patients with no history of drinking or abstinence for more than 1 year
✓. Voluntary participants with informed consent

What they're measuring

amino acids metabolism

Timeframe: 2021.09.01-2022.08.01

central carbon metabolism

Timeframe: 2021.09.01-2022.08.01

Trial details

NCT IDNCT05041348

SponsorThe Affiliated Hospital of Qingdao University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-15

View on ClinicalTrials.gov More Sarcopenia trials